The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring ...
The results of the PHERGuide study, presented during the 2025 San Antonio Breast Cancer Symposium (SABCS), demonstrate that the presence of circulating tumor DNA (ctDNA) is associated with disease stage. This research paves the way for the use of blood- …